OTLK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OTLK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Outlook Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.80. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.00.
Outlook Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.80. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.00.
Outlook Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.80. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.00.
During the past 3 years, the average EPS without NRIGrowth Rate was 29.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 49.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 10 years, Outlook Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 67.10% per year. The lowest was -8.80% per year. And the median was 41.10% per year.
The historical data trend for Outlook Therapeutics's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics Annual Data | |||||||||||||||||||||
Trend | Sep14 | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
EPS (Diluted) | Get a 7-Day Free Trial | -39.60 | -13.40 | -7.00 | -6.20 | -4.80 |
Outlook Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EPS (Diluted) | Get a 7-Day Free Trial | -1.60 | -0.60 | -1.60 | -1.00 | -0.80 |
For the Biotechnology subindustry, Outlook Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Outlook Therapeutics's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Outlook Therapeutics's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as
Diluted EPS (A: Sep. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-58.983 | - | 0) | / | 12.509 | |
= | -4.72 |
Outlook Therapeutics's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as
Diluted EPS (Q: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-11.178 | - | 0) | / | 13.013 | |
= | -0.86 |
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics (NAS:OTLK) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Outlook Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Terry Dagnon | officer: Chief Operating Officer | C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512 |
Jeff Evanson | officer: Chief Commercial Officer | C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512 |
Yezan Munther Haddadin | director | ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844 |
Faisal Ghiath Sukhtian | director | 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844 |
Kurt J Hilzinger | director | 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087 |
Julia A Haller | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Trenary C Russell Iii | director, officer: CEO and President | 1700 E ST ANDREW PLACE, SANTA ANA CA 92705 |
Ghiath M. Sukhtian | director, 10 percent owner | 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844 |
Lawrence A Kenyon | officer: CFO and Secretary | C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512 |
Syntone Ventures Llc | 10 percent owner | 1517 CHAMPLAIN CREST WAY, CARY NC 27513 |
Randy H Thurman | director | 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654 |
Andong Huang | director | C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852 |
Gerd Auffarth | director | C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000 |
Julian S Gangolli | director | 4955 BASELINE AVENUE, SANTA YNEZ CA 93460 |
Gms Ventures & Investments | director | C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007 |
From GuruFocus
By PRNewswire • 12-18-2023
By PRNewswire • 12-26-2023
By Business Wire • 12-07-2023
By PRNewswire • 12-18-2023
By PRNewswire • 12-06-2023
By PRNewswire • 11-30-2023
By PRNewswire • 12-03-2023
By PRNewswire • 11-28-2023
By PRNewswire • 12-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.